[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353664-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353664-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","reducing-ogt-and-o-glcnacylation-enhance-the-anticancer-effects-of-oxaliplatin-in-sw620-metastatic-colorectal-cancer-cells","Reducing OGT and O-GlcNAcylation enhance the anticancer effects of oxaliplatin in SW620 metastatic colorectal cancer cells","","O-GlcNAcylation, a single GlcNAc attachment on serine/threonine residues of nuclear-cytoplasmic proteins, is frequently increased in cancers and linked to tumor progression. Chemotherapeutic treatments can also activate this modification, but its role in colorectal cancer responses remains unclear. This study examines oxaliplatin in SW620 metastatic colorectal cancer cells and shows that OXA reduces viability and proliferation while raising O-GlcNAcylation and GFPT1, and that OGT inhibition markedly enhances OXA sensitivity through apoptosis induction and cell-cycle arrest, supported by proteomics.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/reducing-ogt-and-o-glcnacylation-enhance-the-anticancer-effects-of-oxaliplatin-in-sw620-metastatic-colorectal-cancer-cells/353664/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/reducing-ogt-and-o-glcnacylation-enhance-the-anticancer-effects-of-oxaliplatin-in-sw620-metastatic-colorectal-cancer-cells/353664.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study’s main focus regarding O-GlcNAcylation in colorectal cancer?","Question",{"text":63,"@type":64},"The study investigates how reducing OGT and protein O-GlcNAcylation affects the response of metastatic colorectal cancer cells to oxaliplatin.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does oxaliplatin (OXA) affect SW620 metastatic CRC cells in this work?",{"text":68,"@type":64},"OXA alone reduces cell viability and proliferation and increases protein O-GlcNAcylation as well as GFPT1 levels.",{"name":70,"@type":61,"acceptedAnswer":71},"What changes occur when OGT is inhibited alongside oxaliplatin treatment?",{"text":72,"@type":64},"Genetic knockdown of OGT or chemical inhibition markedly enhances sensitivity to OXA, evidenced by decreased viability and proliferation, increased apoptosis, and cell-cycle arrest, with pathway alterations revealed by proteomics.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353664,1790194989,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","OPEN ACCESS  \nCitation: Bunsuk T, Chantaraamporn J, Mutapat P, Diskul Na Ayudthaya P, Chokchaichamnankit D, Srisomsap C, et al. (2026) Reducing OGT and O-GlcNAcylation enhance the anticancer effects of oxaliplatin in SW620 metastatic colorectal cancer cells. PLoS One 21(2):  \ne0341971. [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0341971  \nEditor: Kihong Lim, University of Rochester,  \nUNITED STATES OF AMERICA Received: June 10, 2025  \nAccepted: January 15, 2026  \nPublished: February 10, 2026  \nCopyright: © 2026 Bunsuk et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All relevant data are within the paper and its Supporting  information files.  \nFunding: This report is part of the research project “Investigation of abnormal biomolecules  \nRESEARCH ARTICLE  \nReducing OGT and O-GlcNAcylation enhance the anticancer effects of oxaliplatin in SW620 metastatic colorectal cancer cells  \nThirasak Bunsuk1☯, Juthamard Chantaraamporn2☯, Photsathorn Mutapat2, Penchatr Diskul Na Ayudthaya2, Daranee Chokchaichamnankit2, Chantragan Srisomsap2, Jisnuson Svasti1,2, Voraratt Champattanachai1,2*  \n1 Applied Biological Sciences: Environmental Health Program, Chulabhorn Graduate Institute, Bangkok, Thailand, 2 Laboratory of Biochemistry, Chulabhorn Research Institute, Bangkok, Thailand  \n☯ These authors contributed equally to this work.  \n* [voraratt@cri.or.th](voraratt@cri.or.th)  \nAbstract  \nO-GlcNAcylation, a single attachment of N-acetylglucosamine (GlcNAc) on serine/ threonine residues of nuclear-cytoplasmic proteins, is frequently upregulated in various cancers and implicated in several aspects of tumor progression. Growing evidence reports that treatments of chemotherapeutic drugs may activate protein O-GlcNAcylation. However, its precise role in modulating chemotherapeutic responses, particularly in colorectal cancer (CRC), remains poorly defined. Herein, we investigate the biological effects of oxaliplatin (OXA), a first-line chemotherapy drug for patients with metastatic CRC, and protein O-GlcNAcylation reduction in SW620 metastatic CRC cells. OXA treatment alone reduced cell viability as well as proliferation, and increased the levels of protein O-GlcNAcylation and GFPT1, the rate limiting enzyme of hexosamine biosynthetic pathway which is a nutrient sensor of glucose metabolism. Inhibition of protein O-GlcNAcylation via genetic knockdown of O-GlcNAc transferase (OGT) or chemical inhibition (OSMI-1) markedly enhanced SW620 sensitive to OXA. This was evidenced by decreased cell viability and proliferation, increased cell apoptosis, and cell cycle arrest. Mass spectrometry-based proteomics and bioinformatics analysis revealed that the combination of OGT knockdown and OXA treatment majorly downregulated several ribosomal proteins.  \nIn addition, OXA treatment and OGT knockdown altered proteins involved in critical pathways including DNA synthesome complex, glycolytic process, negative regulation of gene expression, cell cycle process, and negative regulation of protein phosphorylation. Specifically, OGT downregulated several ribosomal proteins, and OGT knockdown influenced proteins across the identified pathways. Taken together, these findings demonstrate that reducing OGT and protein O-GlcNAcylation may enhance the sensitivity of CRC cells to OXA, and the altered pathways may offer new insights into potential mechanisms for overcoming CRC chemoresistance.  \nPLOS One | [https://doi.org/10.1371/journal.pone.0341971](https://doi.org/10.1371/journal.pone.0341971) February 10, 2026 1 / 19  \nas biomarker targets for cancer detection and precision therapeutics” financially supported by the Thailand Science Research and Innovation (TSRI), Chulabhorn Research Institute (Grant No. 49890/4759795) . Th","cbCaiuOsSVxVACnT","https://ap.wps.com/l/cbCaiuOsSVxVACnT","pdf",3675116,"English","# Abstract\n# Introduction","[{\"question\":\"What is the study’s main focus regarding O-GlcNAcylation in colorectal cancer?\",\"answer\":\"The study investigates how reducing OGT and protein O-GlcNAcylation affects the response of metastatic colorectal cancer cells to oxaliplatin.\"},{\"question\":\"How does oxaliplatin (OXA) affect SW620 metastatic CRC cells in this work?\",\"answer\":\"OXA alone reduces cell viability and proliferation and increases protein O-GlcNAcylation as well as GFPT1 levels.\"},{\"question\":\"What changes occur when OGT is inhibited alongside oxaliplatin treatment?\",\"answer\":\"Genetic knockdown of OGT or chemical inhibition markedly enhances sensitivity to OXA, evidenced by decreased viability and proliferation, increased apoptosis, and cell-cycle arrest, with pathway alterations revealed by proteomics.\"}]","Reducing OGT and O-GlcNAcylation enhance the anticancer effects of oxaliplatin in SW620 metastatic colorectal cancer cells | PDF",1790106626,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8b895ed2e080bc01e43a057083c9ce6.webp",983,1272,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b37ee642d4b36abb920259d39d95e56.webp",982,1270,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e85e02e9cbd310aa911e1a06775b1874.webp",981,1269,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30eaa215325b1d105ac609ad2d30f99d.webp",980,1268]